Also mention amount of anticoagulant and activator calcium chloride to be used
PRP platelet rich plasma preparation anticoagulant sodium citrate calcium chloride activator amounts protocol
https://jcasonline.com/principles-and-methods-of-preparation…
https://www.frontiersin.org/journals/cell-and-developmental-…
PRP preparation sodium citrate 3.2% 1:9 ratio blood collection calcium chloride 10% 50ul per ml activation protocol
| Anticoagulant | Concentration | Ratio to Blood | Notes |
|---|---|---|---|
| Trisodium Citrate (most common) | 3.2% or 3.8% | 1:9 (1 part anticoagulant : 9 parts blood) | Standard for platelet studies; 3.2% preferred for PRP |
| ACD-A (Acid Citrate Dextrose) | Standard formulation | 1:6 to 1:9 (typically 1 mL ACD-A per 6 mL blood) | Considered superior — better platelet morphology, higher TGF-β1 and PDGF-BB concentrations |
| EDTA | — | — | Avoid — dissociates GPIIb/IIIa complex, damages platelet membrane |
| Heparin | — | — | Less preferred; can cause platelet aggregation artefacts |
Practical example: For a 27 mL blood draw (a common PRP protocol), use 3 mL of ACD-A or sodium citrate → yields ~3–5 mL of PRP after centrifugation.
| Parameter | Details |
|---|---|
| Concentration used | 10% CaCl₂ is most commonly cited in literature |
| Volume ratio | 50 µL (0.05 mL) of 10% CaCl₂ per 1 mL of PRP |
| Alternative concentrations | 2.5% CaCl₂ — associated with better cell proliferation and fibroblast adhesion; 5% CaCl₂ — intermediate effect; 10% CaCl₂ — rapid activation but may cause pain (low pH ~6.3) |
| Physiological protocol (Anitua) | Less anticoagulant (0.4 mL of 3.8% sodium citrate) + 20 µL/mL activator |
| Conventional protocol (Anitua) | More anticoagulant (0.9 mL of 3.8% sodium citrate) + 50 µL/mL activator |
| Activator | Dose | Characteristics |
|---|---|---|
| Bovine/autologous thrombin | 10% solution | Immediate growth factor release; risk of immune reaction with bovine thrombin |
| Calcium chloride + thrombin | Combined | Rapid + sustained GF release |
| Collagen type I | 10% | Sustained release; reduces overall GF concentration |
| No activation (endogenous) | — | Adequate for soft tissue injection (collagen in tissue acts as natural activator) |